WealthShield Partners LLC Makes New Investment in Edwards Lifesciences Corporation $EW

WealthShield Partners LLC bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 28,111 shares of the medical research company’s stock, valued at approximately $2,543,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. TrinityBridge Ltd purchased a new position in shares of Edwards Lifesciences during the second quarter valued at $27,000. MV Capital Management Inc. purchased a new stake in Edwards Lifesciences in the fourth quarter worth about $26,000. Hanson & Doremus Investment Management purchased a new stake in Edwards Lifesciences in the first quarter worth about $25,000. Kemnay Advisory Services Inc. bought a new position in Edwards Lifesciences during the 4th quarter worth about $27,000. Finally, JPL Wealth Management LLC bought a new position in Edwards Lifesciences during the 3rd quarter worth about $25,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

EW opened at $89.89 on Friday. The firm has a market capitalization of $51.76 billion, a PE ratio of 51.66, a price-to-earnings-growth ratio of 2.26 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The business’s 50-day moving average is $89.21 and its two-hundred day moving average is $84.67. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $96.29.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same period in the prior year, the firm posted $0.67 earnings per share. The company’s quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Mizuho raised their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Leerink Partners raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $87.00 to $101.00 in a research report on Friday, July 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Finally, Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $100.27.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 619 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares of the company’s stock, valued at $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 25,570 shares of company stock worth $2,219,390 in the last 90 days. 0.31% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.